Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals, Confo Therapeutics to Collaborate on Antibody Discovery

11/30/2021 | 05:54am EST


© MT Newswires 2021
All news about REGENERON PHARMACEUTICALS
01/25GLOBAL MARKETS LIVE : Credit Suisse, Unilever, Nvidia, Tesla, American Express...
01/25WALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
01/25MARKETSCREENER’S WORLD PRESS REVIEW : January 25, 2022
01/24REGENERON PHARMACEUTICALS : U.S. Food and Drug Administration Revises Emergency Use Author..
PU
01/24U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments
RE
01/24U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo
RE
01/24FDA to Restrict Monoclonal Antibodies Manufactured by Eli Lilly, Regeneron Pharmaceutic..
MT
01/24UK to begin testing Merck's COVID pill for hospitalized patients
RE
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Regeneron - FORTY ACCOMPLISHED YOUNG SCIENTISTS NAMED FINALISTS IN THE 2022 REGENERON S..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 548 M - -
Net income 2021 7 971 M - -
Net cash 2021 4 180 M - -
P/E ratio 2021 8,59x
Yield 2021 -
Capitalization 63 282 M 63 282 M -
EV / Sales 2021 3,80x
EV / Sales 2022 4,20x
Nbr of Employees 9 766
Free-Float 81,7%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 605,25 $
Average target price 697,73 $
Spread / Average Target 15,3%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS-4.16%63 282
GILEAD SCIENCES, INC.-7.26%84 470
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812
BEIGENE, LTD.-17.13%23 067